Compare ELLO & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELLO | TRDA |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.0M | 404.4M |
| IPO Year | 1995 | 2021 |
| Metric | ELLO | TRDA |
|---|---|---|
| Price | $28.31 | $10.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 3.4K | ★ 261.0K |
| Earning Date | 12-30-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $48,742,227.00 | ★ $61,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.31 | N/A |
| 52 Week Low | $13.00 | $4.93 |
| 52 Week High | $29.25 | $14.02 |
| Indicator | ELLO | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.44 |
| Support Level | N/A | $9.79 |
| Resistance Level | N/A | $11.82 |
| Average True Range (ATR) | 0.00 | 0.75 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 0.00 | 21.34 |
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.